Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Core Viewpoint - Ventyx Biosciences, a clinical-stage biopharmaceutical company, is focused on developing innovative oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases and will participate in a fireside chat at the Piper Sandler 37 Annual Healthcare Conference [1][2]. Company Overview - Ventyx Biosciences specializes in creating oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, leveraging expertise in medicinal chemistry, structural biology, and immunology to discover differentiated oral small molecule therapeutics [3]. - The company has extensive experience in clinical development, facilitating the rapid progression of drug candidates through clinical trials [3]. Product Portfolio - Ventyx's portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that has completed Phase 2 studies for obesity-related cardiovascular risk factors and Parkinson's disease [4]. - The inflammatory bowel disease portfolio features two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor [4]. Event Details - The fireside chat at the Piper Sandler 37 Annual Healthcare Conference is scheduled for December 3, 2025, from 4:00 to 4:25 PM ET, with a live webcast available on the company's website [2].